Eurobench.com

Wimmie 14 maart 2012 08:20

0

OctoPlus tekent evaluatiecontract LEIDEN (AFN) - Biotechnologiebedrijf OctoPlus heeft een evaluatiecontract verkregen van een bedrijf dat in de top-5 staat van wereldwijde producenten van generieke medicijnen. Dat werd woensdag bekendgemaakt.
De naam van de onderneming en financiële details van de overeenkomst worden niet vrijgegeven. OctoPlus gaat een generieke formulering ontwikkelen van een bestaand injecteerbaar geneesmiddel.

,,Als het project succesvol is kan het contract in de toekomst leiden tot een volledig procesontwikkelings- en productiecontract'', aldus OctoPlus

[verwijderd] 14 maart 2012 12:23

0

leesvoer (oudnieuws?)

www.bmg.gv.at/cms/home/attachments/3/...

[verwijderd] 19 maart 2012 11:46

0

CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery

HELSINKI, Finland, March 15, 2012 /PRNewswire/ -- CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.

The purpose of this study is to demonstrate that Fibrinogen Concentrate (Human)(FCH) can reduce intraoperative bleeding and, therefore, the volume of donor blood products (e.g., fresh frozen plasma, platelets, and red blood cells) needed during complex cardiovascular surgical procedures such as aortic aneurysm surgery. The study will also aim to show that FCH is safe and well tolerated. The primary efficacy endpoint measurement will be the number of units of all allogeneic blood products transfused during the first 24 hours after administration of FCH or placebo. "

Potentially life-threatening bleeding events can occur during cardiovascular surgery because the patient's fibrinogen levels are depleted, which delays clotting," said Dr. Niels Rahe-Meyer, Department of Anesthesiology and Intensive Care, Franziskus Hospital, Bielefeld, Germany and coordinating investigator of the study. "The REPLACE Phase III study will help determine if FCH treatment can safely reduce the number of transfusions needed during cardiovascular surgery. If this is the case, we will have a powerful new option for use in protecting cardiovascular surgery patients from potentially life-threatening bleeding and transfusion-associated adverse events and discomfort."

Of the 12 million units of blood used in the United States each year, 15 percent are used in cardiovascular surgery. Studies have shown that blood transfusion during or after adult cardiac surgery is associated with increased long-term mortality."

As a global leader in the development of plasma-derived and recombinant coagulation factors for bleeding disorders, we are pleased that this important Phase III study of FCH in aortic aneurysm surgery is underway," said Russell Basser, M.D., Senior Vice President, Global Clinical R&D. "CSL Behring is committed to exploring the use of FCH in patients at high risk of bleeding resulting from cardiac surgery and providing optimal, uncompromised therapy to cardiac surgery teams and patients."

About the REPLACE Study

REPLACE (Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery) is a Phase III, prospective, multinational, multicenter, randomized, double-blind, placebo-controlled, two-arm study. Patients undergoing elective thoracic aortic surgery are randomized in a 1:1 ratio to treatment with FCH or placebo. Patients will receive a single intra-operative infusion if their blood loss amounts to 60 to 250g in 5 minutes after initial surgery is completed. Following infusion, a second 5-minute bleeding mass measurement is undertaken. If blood loss then still amounts to 60 g or more, the patient will be treated according to a predefined, standardized treatment regimen using allogeneic blood products. Reduction of allogenic blood products and other efficacy endpoints in addition to safety endpoints will be measured according to the trial protocol. For more information visit www.clinicaltrials.gov and search with identifier: NCT01475669.

[verwijderd] 20 maart 2012 10:24

0

Misschien helpt dit 'onze'koers een beetje?

Het lokaal genoteerde Cryo-Save ging 0,7% omhoog. De stamcelbank zag de omzet in 2011 met 4% stijgen tot €41,9 miljoen. De nettowinst kwam uit op €2,3 miljoen, tegen €2,6 miljoen een jaar eerder. Cryo-Save zei dat de omzet steeg door verhoogde verkoopvolumes in verschillende landen, overnames en een toename van het aantal nieuwe stalen navelstrengweefsels.

[verwijderd] 20 maart 2012 13:13

0

www.sobi.com/en/Investors--Media/News...

voda 21 maart 2012 16:20

0

Galapagos krijgt mijlpaalbetaling van Janssen Pharmaceutica

AMSTERDAM (Dow Jones)--Biotechnologiebedrijf Galapagos nv (GLPG.BT) heeft een preklinisch molecuul geidentificeerd binnen de overeenkomst met Janssen Pharmaceutica nv en ontvangt daarmee een mijlpaalbetaling met EUR6,6 miljoen.

Galapagos stelt nu verder te gaan met het evalueren van de veiligheid, waarna dit molecuul in een Fase I klinische studie zal getest worden.

De overeenkomst tussen Galapagos en Janssen Pharmaceutica stamt uit oktober 2007, waarbij Janssen een optie verkreeg op de wereldwijde commerciële rechten voor bepaalde interne programma's van Galapagos. Per programma kan Galapagos tot EUR73 miljoen aan succesbetalingen per programma ontvangen, plus royalty's.

Galapagos meldt tot nu EUR31 miljoen aan betalingen van Janssen te hebben ontvangen.

- Door Levien de Feijter; Dow Jones Newswires; +31 20 571 52 00; levien.defeijter@dowjones.com

[verwijderd] 22 maart 2012 17:11

0

Watson Pharmaceuticals’ rumoured $7bn takeover of private Swiss company Actavis would be a defensive move to stimulate growth. The transaction would not allow the world’s fourth biggest generics group by sales to challenge the likes of Teva or Novartis’ Sandoz division, but it would keep it ahead of the quickly expanding lookalike arms of Sanofi and Daiichi Sankyo and help establish a stronger global presence

[verwijderd] 23 maart 2012 17:03

0

China Biologic Receives SFDA Approval to Begin Clinical Trials for Human Fibrinogen

BEIJING, March 23, 2012 /PRNewswire-Asia-FirstCall/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China, today announced that its indirectly owned subsidiary, Shandong Taibang Biological Products Co., Ltd. ("Taibang"), recently received approval from the China State Food and Drug Administration ("SFDA") to begin clinical trials for its human fibrinogen to be used to treat congenital fibrinogen deficiency and acquired fibrinogen deficiency.Under Chinese regulations, the Company can begin with the phase III clinical trials, which includes the efficacy study, since phases I and II are not required for this product.

Mr. Chao Ming (Colin) Zhao, China Biologic's President & Chief Executive Officer, said, "We are very pleased to receive the SFDA's approval to enter clinical trials for our human fibrinogen product. Our human fibrinogen is made using our internally developed new manufacturing process, which improves product quality, compared with currently available products in the Chinese market. The new process also increases plasma utilization and production efficiency. We plan to secure a patent for our manufacturing invention. We believe this new product also will advance our plasma protein development pipeline. The phase III clinical trials are expected to last about two years, after which we will begin commercial production and sales, assuming the clinical trials prove that the product provides the safe and effective treatments we expect."

The Company began pre-clinical research in 2008 for its human fibrinogen, including its production process development and pharmaceutical research. In 2009, it completed pre-clinical inactivated virus research and validation work related to the product's development. In 2010, the Company conducted the pilot study for human fibrinogen and in mid-2010 submitted its application to the SFDA for approval to start human clinical trials for its human fibrinogen.

voda 26 maart 2012 16:35

0

Roche verlengt biedingstermijn Illumina
Gepubliceerd op 26 mrt 2012 om 07:37 | Views: 500

ZURICH (AFN) - Het Zwitserse farmacieconcern Roche heeft maandag de biedingstermijn voor het Amerikaanse Illumina verlengd tot 20 april. Het bod zelf blijft onveranderd op 44,50 dollar per aandeel in contanten ofwel circa 5,7 miljard dollar.

Eerder liep de biedingstermijn tot 23 maart. Roche maakte op 27 januari het bod op Illumina bekend. Het bestuur van Illumina heeft het echter als te laag bestempeld en de aandeelhouders geadviseerd het af te wijzen.

Illumina maakt onder meer zogenoemde 'gene sequencing'-apparaten, waarmee DNA in kaart gebracht kan worden.

[verwijderd] 26 maart 2012 16:58

0

Nou,vooruit,een van mijn parade paardjes.
Ben het niet gewoon om mijn doen en laten hier weer te geven.

Hemispherx Publishes Peer-Reviewed Data on an Analysis of the Incidence and Clinical Impact of Neutralizing Antibodies (NABs) Against Recombinant Interferons Versus Natural Human Interferons (IFNs)

Mar 26, 2012 (GlobeNewswire via COMTEX) --

Incidence of NABs Induced Against Natural IFNs, Such as Alferon N
Injection(R), Was Very Low (<0.2%) and Significantly Less Than for
Recombinant IFNs

PHILADELPHIA, March 26, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma Inc. /quotes/zigman/165768/quotes/nls/heb HEB +5.64% announced the publication of a peer-reviewed article in the Journal of Interferon and Cytokine Research (Volume 32, pages 95-102) providing an analysis of the incidence and clinical impact of neutralizing antibodies (NABs) formed during treatment with recombinant interferons (a-2a, a-2b, ß-1a and ß-1b) compared to natural interferons (a-n1 or a-n3), such as Alferon N Injection(R). The recombinant interferons induced seroconversion with the generation of NABs in 17.2% of patients studied. Seroconversion is the development of detectable specific antibodies. Antibodies can sometimes attack a pharmaceutical administered to the body eventually inhibiting the effect of the medication.

In contrast the incidence of antibodies induced against natural interferons was very low, less than 0.2%, and was significantly less than that seen for recombinant interferons (p<0.0001). The fraction of relapsed (responded initially) and refractory (resistant to treatment) patients was greater in NAB positive patients compared to NAB negative patients (p<0.0001).

The percentage of patients who responded to treatment was also higher in the NAB negative group (p<0.0011). Overall, in 82% of the NAB positive patients treated with recombinant interferons, switching to natural interferons restored the clinical response, indicating that the NABs directed against recombinant interferons, do not effectively cross-react with natural interferons. Therefore, the presence of NABs produced against a recombinant interferon does not appear to interfere with the effectiveness of natural interferons.

Alferon N Injection(R) is the registered trademark for Hemispherx's injectable formulation of natural interferon, which is approved by the FDA for the treatment of certain categories of genital warts. According to the Centers for Disease Control and Prevention (CDC), "Approximately 20 million Americans are currently infected with Human papillomavirus (HPV) with another 6 million people becoming newly infected each year. HPV is so common that at least 50% of sexually active men and women get it at some point in their lives. About 1% of sexually active adults in the U.S. have genital warts at any one time. Although treatments exist that can remove the warts, they do not remove the HPV, and so warts can recur after treatment (about 50--73% of the time)." Alferon N Injection(R) is the only natural-source, multispecies a-interferon currently approved for sale in the United States for the intralesional treatment of refractory or recurring external genital warts in patients 18 years or older.

As reported recently, Alferon N Injection(R) (under the brand name "Naturaferon") has been approved for sale and distribution in Argentina. The receipt of the ANMAT (Administracion Nacional de Medicamentos) approval is the first step of a regulatory process towards commercial sales of Naturaferon.

In addition Hemispherx is developing an experimental low-dose, oral liquid formulation of Natural Alpha Interferon, Alferon(R) LDO [Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)] and like Alferon N Injection(R), should not cause antibody formation. Alferon(R) LDO is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa. Oral interferon could be economically feasible for patients and logistically manageable in development programs in third-world countries primarily affected by influenza and other emerging viruses. Oral administration of Alferon(R) LDO, with its anticipated affordability, low toxicity, no production of antibodies, and broad range of potential bioactivity, could be a breakthrough treatment or prevention for viral diseases.

About Hemispherx Biopharma

Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders. Hemispherx's flagship products include Alferon N Injection(R) (FDA approved for a category of sexually transmitted diseases) and the experimental therapeutics Ampligen(R) and Alferon(R) LDO. Ampligen(R) is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon N Injection(R)). The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net .

Information contained in this news release, other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the Company (including Ampligen(R) and Alferon(R) LDO) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. The planning, completion, results or submission of clinical trials do not imply that any study product will ever be approved commercially for the studied or other treatment indications.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Hemispherx Biopharma, Inc.

[verwijderd] 28 maart 2012 13:25

0

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7 (MPS 7). Orphan designation in the European Union provides several benefits including 10 years of market exclusivity post-authorization, fee reductions, scientific assistance for marketing authorization and access to community marketing authorization.

UX001 is an extended release formulation of sialic acid (SA-ER) intended as a substrate replacement therapy for HIBM, a severe, neuromuscular disease caused by sialic acid deficiency. UX003 is a recombinant human?beta-glucuronidase intended as an enzyme replacement therapy for the treatment of MPS 7, an extremely rare autosomal recessive lysosomal storage disorder characterized by a deficiency of the lysosomal enzyme beta-glucuronidase.

Ultragenyx continues to make significant progress in advancing our pipeline of potential treatments for patients affected by ultra-rare diseases, said Emil D. Kakkis, MD, PhD, Chief Executive Officer of Ultragenyx. I am pleased that our regulatory team was able to obtain orphan designation in both the US and the EU so promptly for both of our lead programs. We will continue to work collaboratively with regulatory authorities as our clinical development programs move forward.

A Phase 2 study for UX001 SA-ER in patients with HIBM is planned to begin enrollment in the second quarter of this year. A Phase 1 study for UX003 is anticipated to begin in the first quarter of 2013. Both UX001 and UX003 have been granted orphan designation by the FDA.

[verwijderd] 28 maart 2012 13:40

0

FDA approves additional blood test for viruses linked to leukemia, neurologic diseases

Avioq HTLV-I/II Microelisa System, a test designed to detect antibodies to viruses in donors of human blood and blood components that are associated with several diseases, including some forms of leukemia and neurologic diseases, was approved today by the Food and Drug Administration.

Avioq HTLV-I/II Microelisa System, is the only test now available that can be used to both screen the blood supply for antibodies to Human T-Lymphotropic Virus Type I (HTLV-I) and Human T-Lymphotropic Virus Type II (HTLV-II), and help diagnose infection with these viruses.

Both HTLV-I and HTLV-II can be transmitted through transfusion, reuse of syringes, and by breast feeding from infected mothers. Screening of all blood donors in the U.S for evidence of HTLV infections is required to assure the safety of blood transfusions.

The Avioq HTLV-I/II Microelisa System is intended for screening living individual human donors, including volunteer donors of whole blood and blood components for the presence of HTLV antibodies. It is also approved for testing serum and plasma specimens to screen potential organ donors when specimens are obtained while the donor’s heart is still beating. It is not intended to be used to screen cord blood specimens or cadaveric blood specimens.

Additionally, the test is approved for use as an aid in the diagnosis of HTLV-I or HTLV-II infection and related diseases.

“Since 2008, there has been only one FDA-licensed donor screening test available for detection of antibodies to HTLV,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval provides an additional test for HTLV, providing greater flexibility to blood establishments and helping to assure the safety of the blood supply.”

The Avioq HTLV-I/II Microelisa System can be used manually or with an automated screening system, the ORTHO Summit System.

The Avioq HTLV-I/II Microelisa System is manufactured by Avioq Inc., Research Triangle Park, N.C.

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation’s food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

voda 28 maart 2012 16:43

0

AMT meldt positieve resultaten Glybera
Gepubliceerd op 28 mrt 2012 om 09:42 | Views: 745

AMSTERDAM (AFN) - De gentherapie Glybera van biotechnologiebedrijf Amsterdam Molecular Therapeutics (AMT) kan helpen bij de bestrijding van pancreatitis bij patiënten met lipoproroteïne lipase deficiëntie (LPLD). Dat is uit onderzoek gebleken, zo meldde AMT woensdag.

Volgens chief medical officer Carlos Camozzi geven de utislagen ,,aanvullende en onafhankelijke ondersteuning'' voor de mogelijkheden van Glybera.

AMT ontving vorige maand een verzoek van het Comité voor geneesmiddelen voor menselijk gebruik (CHMP) van het Europees Geneesmiddelenbureau (EMA) om additionele informatie over zijn geneesmiddel Glybera te leveren. Eerder die maand werd bekend dat AMT wordt overgenomen door uniQure en daardoor van de Amsterdamse beurs verdwijnt.

voda 29 maart 2012 16:46

0

Roche verhoogt bod op Illumina
Gepubliceerd op 29 mrt 2012 om 07:20 | Views: 224

ZURICH (AFN) - Het Zwitserse farmacieconcern Roche heeft zijn bod op het Amerikaanse Illumina verhoogd van 44,50 dollar per aandeel naar 51 dollar per aandeel. Dat werd donderdag bekendgemaakt.

De overige voorwaarden blijven gelijk. Roche kondigde onlangs aan de biedingstermijn van het bod te verlengen tot 20 april. Eerder liep de biedingstermijn tot 23 maart.

Roche maakte op 27 januari het bod van 44,50 dollar per aandeel op Illumina bekend. Het bestuur van Illumina bestempelde dat bod als te laag en adviseerde de aandeelhouders het af te wijzen. Illumina maakt onder meer apparaten waarmee DNA in kaart kan worden gebracht.

voda 30 maart 2012 21:20

0

Aandeelhouders AMT stemmen in met overname

AMSTERDAM (Dow Jones)--Aandeelhouders van Amsterdam Molecular Therapeutics nv (AMT.AE) hebben vrijdag tijdens de Buitengewone Vergadering van Aandeelhouders (BAVA) ingestemd met een overname door uniQure BV.

De aandeelhouders hebben een akkoord gegeven voor alle besluiten over de herstructurering van de onderneming en de financiële transactie, laat het bedrijf weten.

De activa en bepaalde passiva van AMT worden overgenomen door de nieuw opgerichte besloten vennootschap, uniQure BV, waarna de beursnotering van AMT beeindigd wordt.

De transactie zal naar verwachting begin april afgerond worden.

Door Ellen Proper; Dow Jones Nieuwsdienst: +31-20-5715200; ellen.proper@dowjones.com

[verwijderd] 2 april 2012 14:20

0

CSL Behring Commences Phase I Study With rVIIa-FP, a Novel Therapy to Treat People With Hemophilia A and Hemophilia B Who Have Inhibitors

KING OF PRUSSIA, Pa., March 30, 2012 /PRNewswire/ -- CSL Behring announced today the first in human dosing of recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Phase I study will investigate in healthy volunteers the safety and pharmacokinetics of rVIIa-FP in comparison to placebo. CSL Behring, in collaboration with its parent company, CSL Limited (ASX: CSL), is developing rVIIa-FP, a novel therapy to treat hemophilia A and hemophilia B patients who have inhibitors as part of the PROLONG 7- FP clinical study program. For more information about this study, please see www.clinicaltrials.gov.

CSL Behring's albumin fusion technology uses albumin as the ideal recombinant genetic fusion partner for coagulation factor proteins due to its inherently long half-life, high potential for tolerability, known mechanism of clearance and low potential for immunogenic reactions. CSL Behring's rVIIa albumin fusion protein is expected to exhibit a good tolerability profile and improved pharmacokinetics that may enable prophylaxis.

CSL Behring's rVIIa-FP was previously granted Orphan Drug Designation by the European Commission and the United States Food and Drug Administration.

voda 3 april 2012 17:11

0

Illumina wijst overnamebod van Roche af
Gepubliceerd op 3 apr 2012 om 07:45 | Views: 249

ZURICH (AFN) - Het Amerikaanse Illumina heeft het verhoogde overnamebod van het Zwitserse farmacieconcern Roche afgewezen. De nieuwe bieding is een ,,dramatische onderwaardering'' van het bedrijf, aldus het bestuur.

Roche verhoogde onlangs het bod op Illumina, dat apparaten maakt waarmee DNA in kaart kan worden gebracht, van 44,50 dollar per aandeel naar 51 dollar per aandeel. Dat waardeert Illumina op 6,7 miljard dollar (zo'n 5 miljard euro).

Het bestuur van Illumina raadt aandeelhouders aan het bod niet te accepteren en aandelen niet aan te bieden. De koers van de onderneming noteerde maandag boven de 51 dollar per aandeel, een signaal dat beleggers een hoger bod niet uitsluiten.

[verwijderd] 4 april 2012 07:55

0

Preklinische data gepresenteerd op de AACR meeting in Chicago

GENT, Belgie, 4 april 2012 - Ablynx [Euronext Brussels: ABLX] heeft vandaag
opgemerkt dat op 3 april 2012 een publicatie rond een nieuwe tetramere
Nanobody(®)-agonist (TAS266) die is gericht tegen de celdood receptor 5 (DR5),
een belangrijke doelwitreceptor op tumorcellen bij een reeks van tumoren, is
gepubliceerd door Novartis op de American Association for Research Cancer Annual
Meeting 2012 in Chicago, USA. Het vermogen van TAS266 om DR5 doelwitreceptoren
efficient te 'cross-linken', hetgeen naar verluid niet kan worden bereikt met
monoklonale antilichamen, leidt tot de gecontroleerde celdood van tumorcellen.

De publicatie is gepresenteerd door Dr Heather Huet van Novartis, en drie
wetenschappers van Ablynx behoren tevens tot de auteurs.

Het abstract vat de resultaten samen van de preklinische in vitro en in vivo
studies van een tetravalent Nanobody tegen DR5 in het gebied van de oncologie.
Het werd aangetoond dat TAS266 een langdurige regressie van de tumor kan
opwekken in meerdere tumormodellen, waaronder een model voor primaire
alvleesklierkanker op basis van uit patiënten verkregen tumoren dat niet
gevoelig is voor een conventioneel anti-DR5 agonistisch antilichaam. Verder
bleek TAS266, vergeleken met een aantal andere therapeutische agonisten tegen
DR5 die ontwikkeld en in klinische evaluatie zijn, 1000-voudig meer werkzaam te
zijn in relevante celmodellen.

Gezien dit alles concluderen de auteurs van het abstract dat "TAS266 has the
potential for superior clinical activity in settings insensitive to the
conventional therapeutic approaches to DR5."

Het abstract vermeldt verder dat "first-in-man trials for TAS266 are expected to
begin in 2012."

Link naar het gepresenteerde abstract: "TAS266, a novel tetrameric Nanobody
agonist targeting death receptor 5 (DR5), elicits superior anti-tumor efficacy
than conventional DR5-targeted approaches."

Dr Edwin Moses, Voorzitter en Gedelegeerd Bestuurder van Ablynx, gaf het
volgende commentaar:

"DR5, dat aanwezig is op de tumorcellen van een groot aantal verschillende
soorten tumoren, is het doelwit geweest van verschillende methodologieën op
basis van conventionele antilichamen, maar geen van deze is tot op heden
succesvol geweest, mogelijk omdat secundaire 'cross-linking' nodig is om de
gewenste activiteit te bereiken. Het vermogen om tetravalente Nanobodies te
maken maakt het, naar het zich laat aanzien, mogelijk om een efficiëntere
'cross-linking' te bereiken en op deze manier potentieel toegang te geven tot
een nieuwe route voor het behandelen van bepaalde tumoren."

Over Ablynx

Ablynx is een biofarmaceutische onderneming die zich toelegt op het onderzoek
naar en de ontwikkeling van Nanobodies(®), een nieuwe klasse van therapeutische
proteïnen, op basis van fragmenten van enkel-domein antilichamen, voor diverse
ernstige en levensbedreigende menselijke ziekten, met inbegrip van ontstekingen,
hematologie, oncologie en ademhalingsziekten. Vandaag heeft de Vennootschap meer
dan 25 projecten in de product portefeuille en zeven Nanobodies in klinische
ontwikkeling. Ablynx heeft lopende onderzoeksovereenkomsten en belangrijke
samenwerkings-akkoorden met verscheidene grote farmaceutische bedrijven,
waaronder Boehringer Ingelheim, Merck Serono en Novartis. De Vennootschap heeft
haar hoofdzetel in Gent, België. Voor meer informatie kunt u terecht op
www.ablynx.com.

Voor bijkomende informatie, gelieve contact op te nemen met

Ablynx:
Dr Edwin Moses
Voorzitter en Gedelegeerd Bestuurder
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

M:Communications:
Mary-Jane Elliott, Amber Bielecka, Claire Dickinson
t: +44 207 920 2330
e: ablynx@mcomgroup.com

Complete versie van het persbericht:
hugin.info/137912/R/1599978/504950.pdf

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE
[HUG#1599978]

www.ablynx.com
(END) Dow Jones Newswires
April 04, 2012 01:02 ET (05:02 GMT)

AAND ABLYNX NV
BE0003877942

voda 5 april 2012 18:16

0

Lijkt Pharming wel. :-)

Galapagos verhoogt aandelenkapitaal door uitoefenen van warrants

AMSTERDAM (Dow Jones)--Biotechnologiebedrijf Galapagos nv (GLPG.BT)verhoogt zijn aandelenkapitaal door het uitoefenen van warrants door personeel, meldt het concern donderdag nabeurs.

Daarmee heeft het concern op 5 april 2012 137.414 nieuwe aandelen uitgegeven ter waarde van EUR1,1 miljoen.

Het concern gebruikt de warrantplannen als onderdeel van zijn beloningssysteem voor personeel en management.

Door Patrick Buis; Dow Jones Nieuwsdienst +31-20-571-52-01; patrick.buis@dowjones.com

[verwijderd] 6 april 2012 08:51

0

www.sobi.com/Global/Financial%20infor...

Vertraagd	7 mrt 2025 09:30
Koers	0,778
Verschil	+0,008 (+1,04%)
Hoog	0,778
Laag	0,764
Volume	1.420.074
Volume gemiddeld	5.915.527
Volume gisteren	19.214.251

04 mrt	Groen licht voor nieuwe CEO Pharming
04 mrt	Rode koersenborden nu de mondiale han...
03 mrt	Groene futures, Trump praat crypto's ...
20 feb	Pharming heeft bijna 93% van Abliva i...	1
07 feb	Pharming verklaart bod op Abliva onvo...
21 jan	Pharming stemt over nieuwe CEO
21 jan	Pharming presenteert nieuwe CEO
16 jan	Fundlogic verkoopt bijna geheel belan...	4
15 jan	Fundlogic flink groter in Pharming	1
07 jan	DWS meldt groter belang in Pharming

Pharming « Terug naar discussie overzicht

Sectornieuws - biotech

Meedoen aan de discussie?

Direct naar Forum

Detail

Pharming nieuws